Salud financiera de hoja de balance de ImpediMed

Salud financiera controles de criterios 6/6

ImpediMed tiene un patrimonio de los accionistas total de A$51.0M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$58.6M y A$7.6M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$36.91m
Patrimonio	AU$50.99m
Total pasivo	AU$7.60m
Activos totales	AU$58.59m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

Recent updates

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Mar 05

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Nov 23

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

Jul 11

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Mar 27

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$41.5M) de IPD superan a sus pasivos a corto plazo (A$5.9M).

Pasivo a largo plazo: Los activos a corto plazo de IPD (A$41.5M) superan a sus pasivos a largo plazo (A$1.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: IPD está libre de deudas.

Reducción de la deuda: IPD no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IPD tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: IPD dispone de suficiente cash runway para 1.8 años si el flujo de caja libre sigue creciendo a tasas históricas de 2.1% cada año.

Salud financiera de hoja de balance de ImpediMed

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Recent updates

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference

No longer forecast to breakeven

Consensus revenue estimates fall by 21%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up